Do analysts recommend TRIB or TELA?

TELA Bio has a consensus price target of $2.20, indicating a potential upside of 241.46%. Given TELA Bio's stronger consensus rating and higher possible upside, analysts plainly believe TELA Bio is more favorable than Trinity Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trinity Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TELA Bio 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is TRIB or TELA more profitable?

TELA Bio has a net margin of -51.53% compared to Trinity Biotech's net margin of -70.06%. Trinity Biotech's return on equity of 0.00% beat TELA Bio's return on equity. Company Net Margins Return on Equity Return on Assets Trinity Biotech -70.06% N/A -32.13% TELA Bio -51.53% -4,549.79% -59.39%

Does the media prefer TRIB or TELA?

In the previous week, TELA Bio had 4 more articles in the media than Trinity Biotech. MarketBeat recorded 7 mentions for TELA Bio and 3 mentions for Trinity Biotech. Trinity Biotech's average media sentiment score of 1.17 beat TELA Bio's score of -0.26 indicating that Trinity Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trinity Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TELA Bio 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer TRIB or QTEX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trinity Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Inspira Technologies OXY B.H.N. 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, TRIB or QTEX?

Inspira Technologies OXY B.H.N. has lower revenue, but higher earnings than Trinity Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trinity Biotech $43.78M 0.18 -$37.38M -$44.26 N/A Inspira Technologies OXY B.H.N. $290K 121.47 -$13.22M N/A N/A

Is TRIB or QTEX more profitable?

Inspira Technologies OXY B.H.N. has a net margin of 0.00% compared to Trinity Biotech's net margin of -70.06%. Company Net Margins Return on Equity Return on Assets Trinity Biotech -70.06% N/A -32.13% Inspira Technologies OXY B.H.N. N/A N/A N/A

Does the media refer more to TRIB or QTEX?

In the previous week, Trinity Biotech had 1 more articles in the media than Inspira Technologies OXY B.H.N.. MarketBeat recorded 3 mentions for Trinity Biotech and 2 mentions for Inspira Technologies OXY B.H.N.. Trinity Biotech's average media sentiment score of 1.17 beat Inspira Technologies OXY B.H.N.'s score of 0.63 indicating that Trinity Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trinity Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inspira Technologies OXY B.H.N. 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer TRIB or ELUT?

Elutia has a consensus price target of $6.00, indicating a potential upside of 537.62%. Given Elutia's stronger consensus rating and higher probable upside, analysts plainly believe Elutia is more favorable than Trinity Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trinity Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Elutia 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is TRIB or ELUT more profitable?

Elutia has a net margin of 426.93% compared to Trinity Biotech's net margin of -70.06%. Trinity Biotech's return on equity of 0.00% beat Elutia's return on equity. Company Net Margins Return on Equity Return on Assets Trinity Biotech -70.06% N/A -32.13% Elutia 426.93% -1,071.47% -45.79%

Does the media prefer TRIB or ELUT?

In the previous week, Elutia had 4 more articles in the media than Trinity Biotech. MarketBeat recorded 7 mentions for Elutia and 3 mentions for Trinity Biotech. Trinity Biotech's average media sentiment score of 1.17 beat Elutia's score of 0.09 indicating that Trinity Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trinity Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elutia 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ARAY or TRIB?

Accuray currently has a consensus price target of $2.00, suggesting a potential upside of 618.91%. Given Accuray's stronger consensus rating and higher possible upside, equities analysts clearly believe Accuray is more favorable than Trinity Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Accuray 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Trinity Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, ARAY or TRIB?

Accuray has higher revenue and earnings than Trinity Biotech. Accuray is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Accuray $458.51M 0.07 -$1.59M -$0.37 N/A Trinity Biotech $43.78M 0.18 -$37.38M -$44.26 N/A

Is ARAY or TRIB more profitable?

Accuray has a net margin of -10.76% compared to Trinity Biotech's net margin of -70.06%. Trinity Biotech's return on equity of 0.00% beat Accuray's return on equity. Company Net Margins Return on Equity Return on Assets Accuray -10.76% -79.43% -10.38% Trinity Biotech -70.06% N/A -32.13%

Does the media favor ARAY or TRIB?

In the previous week, Trinity Biotech had 1 more articles in the media than Accuray. MarketBeat recorded 3 mentions for Trinity Biotech and 2 mentions for Accuray. Trinity Biotech's average media sentiment score of 1.17 beat Accuray's score of 0.94 indicating that Trinity Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Accuray 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trinity Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer BEAT or TRIB?

HeartBeam presently has a consensus target price of $4.00, suggesting a potential upside of 701.12%. Given HeartBeam's stronger consensus rating and higher probable upside, analysts clearly believe HeartBeam is more favorable than Trinity Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HeartBeam 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.67 Trinity Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BEAT or TRIB more profitable?

HeartBeam has a net margin of 0.00% compared to Trinity Biotech's net margin of -70.06%. Trinity Biotech's return on equity of 0.00% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets HeartBeam N/A -1,670.91% -481.40% Trinity Biotech -70.06% N/A -32.13%

Does the media favor BEAT or TRIB?

In the previous week, HeartBeam had 2 more articles in the media than Trinity Biotech. MarketBeat recorded 5 mentions for HeartBeam and 3 mentions for Trinity Biotech. Trinity Biotech's average media sentiment score of 1.17 beat HeartBeam's score of -0.23 indicating that Trinity Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HeartBeam 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Trinity Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Trinity Biotech (TRIB) Competitors

$11.67 -0.20 (-1.68%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$11.71 +0.04 (+0.34%)

As of 08/14/2026 07:34 PM Eastern

Compare

TRIB vs. TELA, QTEX, ELUT, ARAY, and BEAT

Should you buy Trinity Biotech stock or one of its competitors? Trinity Biotech's main competitors and comparable companies include TELA Bio (TELA), Inspira Technologies OXY B.H.N. (QTEX), Elutia (ELUT), Accuray (ARAY), and HeartBeam (BEAT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does Trinity Biotech compare to TELA Bio?

Trinity Biotech (NASDAQ:TRIB) and TELA Bio (NASDAQ:TELA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

TELA Bio has a net margin of -51.53% compared to Trinity Biotech's net margin of -70.06%. Trinity Biotech's return on equity of 0.00% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trinity Biotech	-70.06%	N/A	-32.13%
TELA Bio	-51.53%	-4,549.79%	-59.39%

Trinity Biotech has higher earnings, but lower revenue than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trinity Biotech	$43.78M	0.18	-$37.38M	-$44.26	N/A
TELA Bio	$79.91M	0.36	-$38.83M	-$0.77	N/A

79.0% of Trinity Biotech shares are owned by institutional investors. Comparatively, 94.3% of TELA Bio shares are owned by institutional investors. 8.2% of Trinity Biotech shares are owned by insiders. Comparatively, 5.1% of TELA Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

TELA Bio has a consensus price target of $2.20, indicating a potential upside of 241.46%. Given TELA Bio's stronger consensus rating and higher possible upside, analysts plainly believe TELA Bio is more favorable than Trinity Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trinity Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, TELA Bio had 4 more articles in the media than Trinity Biotech. MarketBeat recorded 7 mentions for TELA Bio and 3 mentions for Trinity Biotech. Trinity Biotech's average media sentiment score of 1.17 beat TELA Bio's score of -0.26 indicating that Trinity Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trinity Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TELA Bio	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

TELA Bio beats Trinity Biotech on 9 of the 15 factors compared between the two stocks.

How does Trinity Biotech compare to Inspira Technologies OXY B.H.N.?

Trinity Biotech (NASDAQ:TRIB) and Inspira Technologies OXY B.H.N. (NASDAQ:QTEX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

In the previous week, Trinity Biotech had 1 more articles in the media than Inspira Technologies OXY B.H.N.. MarketBeat recorded 3 mentions for Trinity Biotech and 2 mentions for Inspira Technologies OXY B.H.N.. Trinity Biotech's average media sentiment score of 1.17 beat Inspira Technologies OXY B.H.N.'s score of 0.63 indicating that Trinity Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trinity Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inspira Technologies OXY B.H.N.	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

79.0% of Trinity Biotech shares are held by institutional investors. Comparatively, 12.7% of Inspira Technologies OXY B.H.N. shares are held by institutional investors. 8.2% of Trinity Biotech shares are held by company insiders. Comparatively, 29.4% of Inspira Technologies OXY B.H.N. shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Inspira Technologies OXY B.H.N. has lower revenue, but higher earnings than Trinity Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trinity Biotech	$43.78M	0.18	-$37.38M	-$44.26	N/A
Inspira Technologies OXY B.H.N.	$290K	121.47	-$13.22M	N/A	N/A

Inspira Technologies OXY B.H.N. has a net margin of 0.00% compared to Trinity Biotech's net margin of -70.06%.

Company	Net Margins	Return on Equity	Return on Assets
Trinity Biotech	-70.06%	N/A	-32.13%
Inspira Technologies OXY B.H.N.	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trinity Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Inspira Technologies OXY B.H.N.	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Inspira Technologies OXY B.H.N. beats Trinity Biotech on 5 of the 9 factors compared between the two stocks.

How does Trinity Biotech compare to Elutia?

Trinity Biotech (NASDAQ:TRIB) and Elutia (NASDAQ:ELUT) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

Elutia has lower revenue, but higher earnings than Trinity Biotech. Trinity Biotech is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trinity Biotech	$43.78M	0.18	-$37.38M	-$44.26	N/A
Elutia	$12.29M	3.28	$53.38M	$0.95	0.99

Elutia has a net margin of 426.93% compared to Trinity Biotech's net margin of -70.06%. Trinity Biotech's return on equity of 0.00% beat Elutia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trinity Biotech	-70.06%	N/A	-32.13%
Elutia	426.93%	-1,071.47%	-45.79%

In the previous week, Elutia had 4 more articles in the media than Trinity Biotech. MarketBeat recorded 7 mentions for Elutia and 3 mentions for Trinity Biotech. Trinity Biotech's average media sentiment score of 1.17 beat Elutia's score of 0.09 indicating that Trinity Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trinity Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elutia	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Elutia has a consensus price target of $6.00, indicating a potential upside of 537.62%. Given Elutia's stronger consensus rating and higher probable upside, analysts plainly believe Elutia is more favorable than Trinity Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trinity Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Elutia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

79.0% of Trinity Biotech shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 8.2% of Trinity Biotech shares are held by company insiders. Comparatively, 17.8% of Elutia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Elutia beats Trinity Biotech on 10 of the 15 factors compared between the two stocks.

How does Trinity Biotech compare to Accuray?

Accuray (NASDAQ:ARAY) and Trinity Biotech (NASDAQ:TRIB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Accuray has a net margin of -10.76% compared to Trinity Biotech's net margin of -70.06%. Trinity Biotech's return on equity of 0.00% beat Accuray's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Accuray	-10.76%	-79.43%	-10.38%
Trinity Biotech	-70.06%	N/A	-32.13%

Accuray currently has a consensus price target of $2.00, suggesting a potential upside of 618.91%. Given Accuray's stronger consensus rating and higher possible upside, equities analysts clearly believe Accuray is more favorable than Trinity Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accuray	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Trinity Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Trinity Biotech had 1 more articles in the media than Accuray. MarketBeat recorded 3 mentions for Trinity Biotech and 2 mentions for Accuray. Trinity Biotech's average media sentiment score of 1.17 beat Accuray's score of 0.94 indicating that Trinity Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Accuray	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trinity Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Accuray has higher revenue and earnings than Trinity Biotech. Accuray is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accuray	$458.51M	0.07	-$1.59M	-$0.37	N/A
Trinity Biotech	$43.78M	0.18	-$37.38M	-$44.26	N/A

64.1% of Accuray shares are held by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are held by institutional investors. 4.4% of Accuray shares are held by company insiders. Comparatively, 8.2% of Trinity Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Accuray and Trinity Biotech tied by winning 7 of the 14 factors compared between the two stocks.

How does Trinity Biotech compare to HeartBeam?

HeartBeam (NASDAQ:BEAT) and Trinity Biotech (NASDAQ:TRIB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

In the previous week, HeartBeam had 2 more articles in the media than Trinity Biotech. MarketBeat recorded 5 mentions for HeartBeam and 3 mentions for Trinity Biotech. Trinity Biotech's average media sentiment score of 1.17 beat HeartBeam's score of -0.23 indicating that Trinity Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HeartBeam	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Trinity Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

HeartBeam has a net margin of 0.00% compared to Trinity Biotech's net margin of -70.06%. Trinity Biotech's return on equity of 0.00% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-1,670.91%	-481.40%
Trinity Biotech	-70.06%	N/A	-32.13%

HeartBeam presently has a consensus target price of $4.00, suggesting a potential upside of 701.12%. Given HeartBeam's stronger consensus rating and higher probable upside, analysts clearly believe HeartBeam is more favorable than Trinity Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
Trinity Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

7.8% of HeartBeam shares are owned by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are owned by institutional investors. 18.0% of HeartBeam shares are owned by insiders. Comparatively, 8.2% of Trinity Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

HeartBeam has higher earnings, but lower revenue than Trinity Biotech. HeartBeam is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01M	-$0.56	N/A
Trinity Biotech	$43.78M	0.18	-$37.38M	-$44.26	N/A

Summary

HeartBeam beats Trinity Biotech on 9 of the 15 factors compared between the two stocks.

Get Trinity Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRIB vs. The Competition

Export

Metric	Trinity Biotech	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.01M	$5.81B	$7.02B	$13.07B
Dividend Yield	N/A	1.76%	2.57%	10.45%
P/E Ratio	-0.26	26.59	270.72	25.33
Price / Sales	0.18	63.22	574.35	73.89
Price / Cash	N/A	33.92	70.48	50.90
Price / Book	-0.02	6.17	12.92	6.25
Net Income	-$37.38M	$149.27M	$3.45B	$347.82M
7 Day Performance	-6.11%	2.04%	1.15%	1.08%
1 Month Performance	8.09%	4.17%	1.37%	0.82%
1 Year Performance	-75.99%	9.34%	62.52%	20.99%

Trinity Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRIB Trinity Biotech	1.1136 of 5 stars	$11.67 -1.7%	N/A	-79.6%	$8.01M	$43.78M	N/A	480	News Coverage Positive News Short Interest Decrease Gap Up
TELA TELA Bio	2.2659 of 5 stars	$0.82 -12.2%	$2.20 +169.3%	-59.7%	$36.58M	$80.28M	N/A	120	Earnings Report
QTEX Inspira Technologies OXY B.H.N.	0.1792 of 5 stars	$1.01 -3.4%	N/A	N/A	$36.31M	$290K	N/A	20
ELUT Elutia	3.3039 of 5 stars	$0.85 +3.8%	$6.00 +610.1%	-56.2%	$36.11M	$12.29M	0.98	180	News Coverage Earnings Report Gap Up
ARAY Accuray	2.0654 of 5 stars	$0.29 -0.1%	$2.00 +584.9%	-80.9%	$34.74M	$458.51M	N/A	1,040	Upcoming Earnings Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRIB) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trinity Biotech (TRIB) Competitors

TRIB vs. TELA, QTEX, ELUT, ARAY, and BEAT

How does Trinity Biotech compare to TELA Bio?

Summary

How does Trinity Biotech compare to Inspira Technologies OXY B.H.N.?

Summary

How does Trinity Biotech compare to Elutia?

Summary

How does Trinity Biotech compare to Accuray?

Summary

How does Trinity Biotech compare to HeartBeam?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRIB vs. The Competition

Trinity Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Trinity Biotech (TRIB) Competitors

TRIB vs. TELA, QTEX, ELUT, ARAY, and BEAT

How does Trinity Biotech compare to TELA Bio?

Is TRIB or TELA more profitable?

Which has higher valuation and earnings, TRIB or TELA?

Do institutionals & insiders believe in TRIB or TELA?

Do analysts recommend TRIB or TELA?

Does the media prefer TRIB or TELA?

Summary

How does Trinity Biotech compare to Inspira Technologies OXY B.H.N.?

Does the media refer more to TRIB or QTEX?

Do institutionals & insiders believe in TRIB or QTEX?

Which has higher earnings and valuation, TRIB or QTEX?

Is TRIB or QTEX more profitable?

Do analysts prefer TRIB or QTEX?

Summary

How does Trinity Biotech compare to Elutia?

Which has higher valuation & earnings, TRIB or ELUT?

Is TRIB or ELUT more profitable?

Does the media prefer TRIB or ELUT?

Do analysts prefer TRIB or ELUT?

Do institutionals and insiders believe in TRIB or ELUT?

Summary

How does Trinity Biotech compare to Accuray?

Is ARAY or TRIB more profitable?

Do analysts prefer ARAY or TRIB?

Does the media favor ARAY or TRIB?

Which has better earnings & valuation, ARAY or TRIB?

Do insiders and institutionals have more ownership in ARAY or TRIB?

Summary

How does Trinity Biotech compare to HeartBeam?

Does the media favor BEAT or TRIB?

Is BEAT or TRIB more profitable?

Do analysts prefer BEAT or TRIB?

Do insiders & institutionals have more ownership in BEAT or TRIB?

Which has preferable valuation & earnings, BEAT or TRIB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRIB vs. The Competition

Trinity Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools